A study performed by researchers at the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC) from the Spanish National Research Council (CSIC) in collaboration with Stony Brook University (USA) proposes a new strategy for the development of new drugs based on the inhibition of tyrosine kinase enzymes, molecules that activate and trigger many cellular processes. The results have been published in the Chemistry - A European Journal.
Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary. The phase III trial is the first to report data comparing a neoadjuvant anti-HER2 based regimen with or without the anti-PD-L1 antibody atezolizumab in patients with high-risk, HER2-positive early breast cancer.
In our study, we constructed a detecting platform based on TpTta-COF nanosheets and fluorescent probe. The TpTta-COF nanosheets can adsorb single-stranded DNA (ss-DNA) probes and quench the fluorescence of ss-DNA. The method enables to capture miR-205 sensitively in aqueous solution with a detection limit of 4.78 nM in the range 0-500 nM and R2 = 0.989, and the method offers great specificity in that it can distinguish the target miRNA from mismatch non-target miRNAs.
Osaka University researchers create an intelligent nanopore system sensitive enough to detect single SARS-CoV-2 virus particles. By training a machine-learning algorithm, the platform was able to identify between various coronaviruses in just five minutes. This work may lead to fast and accurate point-of-care testing for COVID and other communicable diseases.
A new treatment approach focused on fixing cell damage, rather than fighting the virus directly, is effective against SARS-CoV-2 in lab models. Combination of two drugs reduces spread of SARS-CoV-2 infection in cells by up to 99.5%. If found safe for human use, this anti-viral treatment would make COVID-19 symptoms milder and speed up recovery times.
Scientists are already preparing for a possible next coronavirus pandemic to strike, keeping with the seven-year pattern since 2004. In future-looking research, scientists have identified a novel target for a drug to treat SARS-CoV-2 that also could impact a new emerging coronavirus. "God forbid we need this, but we will be ready," said the lead Northwestern scientist.
The accumulation of micro- and nanoplastics in the environment continues at an alarming rate. A radiolabelling technique developed at the University of Helsinki made it possible to monitor the movement and accumulation of plastics in the mouse body, as well as their elimination from it.
New research published in BMJ Open shows that community pharmacy could play a 'key clinical role' in the future of COVID-19 vaccination programmes, according to a study led by Aston University in Birmingham, UK, in collaboration with UK and international researchers.
Nanoengineers at the University of California San Diego have developed immune cell-mimicking nanoparticles that target inflammation in the lungs and deliver drugs directly where they're needed. As a proof of concept, the researchers filled the nanoparticles with the drug dexamethasone and administered them to mice with inflamed lung tissue. Inflammation was completely treated in mice given the nanoparticles, at a drug concentration where standard delivery methods did not have any efficacy.
Evaluation of three COVID-19 vaccine candidates in 2020-21 during a worldwide pandemic was unprecedented in terms of urgency and scope. Responsibility for the safety, integrity and scientific validity of U.S. trials fell to 12 experts of the federally appointed COVID-19 Vaccine Data and Safety Monitoring Board, who in turn report to an oversight group. This team has now taken the unusual step of publishing details of their review process in The Journal of Infectious Diseases.